Profile data is unavailable for this security.
About the company
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
- Revenue in USD (TTM)6.98m
- Net income in USD-144.49m
- Incorporated2011
- Employees68.00
- LocationSyros Pharmaceuticals Inc35 Cambridge Park DriveCAMBRIDGE 02140United StatesUSA
- Phone+1 (617) 744-1340
- Fax+1 (617) 744-1377
- Websitehttps://syros.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Citius Pharmaceuticals Inc | 0.00 | -37.35m | 126.02m | 22.00 | -- | 1.40 | -- | -- | -0.2367 | -0.2367 | 0.00 | 0.4989 | 0.00 | -- | -- | 0.00 | -37.14 | -30.26 | -39.48 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
Biostem Technologies Inc | 58.01m | 159.39k | 126.63m | 67.00 | -- | 19.22 | 329.80 | 2.18 | -0.0865 | -0.0865 | 3.60 | 0.4064 | 2.38 | 5.17 | 2.78 | -- | 0.6536 | -- | 9.45 | -- | 94.16 | -- | 0.2748 | -- | 1.10 | 1.23 | 0.3959 | -- | -- | -- | -- | -- | -- | -- |
CytomX Therapeutics Inc | 119.18m | 16.53m | 132.46m | 120.00 | 8.60 | -- | 7.13 | 1.11 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
Gossamer Bio Inc | 0.00 | -172.58m | 133.47m | 135.00 | -- | 4.99 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
I-Mab ADR | 3.82m | -202.40m | 134.09m | 220.00 | -- | 0.5639 | -- | 35.12 | -2.43 | -2.43 | 0.0459 | 2.94 | 0.0083 | -- | -- | 17,352.01 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
Tevogen Bio Holdings Inc | 0.00 | -67.33k | 134.14m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 135.11m | 28.00 | -- | 3.17 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
Syros Pharmaceuticals Inc | 6.98m | -144.49m | 136.31m | 68.00 | -- | 9.05 | -- | 19.53 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
Rapt Therapeutics Inc | 0.00 | -118.05m | 139.55m | 126.00 | -- | 1.07 | -- | -- | -3.07 | -3.07 | 0.00 | 3.76 | 0.00 | -- | -- | 0.00 | -58.42 | -46.30 | -65.33 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
Scpharmaceuticals Inc | 17.63m | -57.71m | 140.97m | 135.00 | -- | 5.74 | -- | 8.00 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
FitLife Brands Inc | 58.51m | 7.30m | 141.12m | 37.00 | 20.75 | 4.80 | 19.04 | 2.41 | 1.48 | 1.48 | 11.87 | 6.39 | 1.20 | 3.87 | 27.13 | 1,581,351.00 | 15.03 | 26.40 | 19.37 | 33.92 | 41.55 | 42.09 | 12.48 | 17.65 | 0.5177 | 12.32 | 0.3582 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
Cardiff Oncology Inc | 610.00k | -40.25m | 142.22m | 31.00 | -- | 2.33 | -- | 233.15 | -0.901 | -0.901 | 0.0137 | 1.36 | 0.0068 | -- | 1.14 | 19,677.42 | -44.55 | -31.24 | -50.10 | -33.56 | -- | -- | -6,594.92 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
Vaxart Inc | 8.89m | -81.74m | 144.12m | 109.00 | -- | 2.58 | -- | 16.22 | -0.5431 | -0.5431 | 0.059 | 0.3155 | 0.0813 | -- | 21.67 | 81,513.76 | -74.81 | -49.60 | -86.63 | -54.86 | -- | -- | -920.00 | -1,398.00 | -- | -- | 0.0705 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
Repare Therapeutics Inc | 97.86m | -45.69m | 147.71m | 179.00 | -- | 0.6313 | -- | 1.51 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Holder | Shares | % Held |
---|---|---|
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 2.51m | 9.37% |
Adage Capital Management LPas of 31 Mar 2024 | 2.07m | 7.75% |
Avidity Partners Management LPas of 31 Mar 2024 | 1.67m | 6.26% |
Point72 Asset Management LPas of 31 Mar 2024 | 1.47m | 5.51% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 924.27k | 3.46% |
Deep Track Capital LPas of 31 Mar 2024 | 828.49k | 3.10% |
Opaleye Management, Inc.as of 31 Mar 2024 | 787.55k | 2.95% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 446.59k | 1.67% |
Kennedy Capital Management LLCas of 31 Mar 2024 | 404.91k | 1.52% |
Walleye Capital LLCas of 31 Mar 2024 | 284.94k | 1.07% |